BG Medicine, Inc. Announces Availability of Galectin-3 Diagnostic Testing Through Mayo Medical Laboratories

BG Medicine, Inc. Announces Availability of Galectin-3 Diagnostic Testing Through Mayo Medical Laboratories

May 14, 2012

WALTHAM, Mass., May 14, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, announced today that Mayo Medical Laboratory (Mayo) now offers galectin-3 testing services to its laboratory customers and physicians. Mayo will offer the BGM Galectin-3TM test, which was cleared by the U.S.

BG Medicine Announces Publication of First Study on Use of Galectin-3 inSelection of Drug Therapy in Heart Failure

BG Medicine Announces Publication of First Study on Use of Galectin-3 inSelection of Drug Therapy in Heart Failure

May 14, 2012

WALTHAM, Mass., May 14, 2012 (GlobeNewswire via COMTEX) -- BG Medicine, Inc.

Eleven Biotherapeutics Secures $20 Million and Expands Series A Financing

Eleven Biotherapeutics Secures $20 Million and Expands Series A Financing

May 8, 2012

Company to Advance its lead Drug Candidate, EBI-005, into Clinic Development for Dry Eye Disease

US Scientists Who Mean Business

US Scientists Who Mean Business

May 6, 2012

 

Vaccine Could Stop Nicotine from Reaching the Brain

Vaccine Could Stop Nicotine from Reaching the Brain

May 1, 2012

The new antismoking technique uses nanoparticles to trigger an immune response.

By Conor Myhrvold

Seahorse Announces the XF Glycolysis Stress Test Kit

Seahorse Announces the XF Glycolysis Stress Test Kit

April 25, 2012

BILLERICA, Mass., April 25, 2012 -- /PRNewswire/ -- Seahorse Bioscience, the leader in cellular bioenergetic measurements, announced the launch of its newest stress test kit at the American Association of Cancer Research (AACR) Annual Meeting 2012. The XF Glycolysis Stress Test Kit is the first Standard for measuring glycolytic capacity in cells.

Dr. Noubar Afeyan, Flagship's Managing Partner and CEO, speaking on Investor Panel at BIO World Congress on Industrial Biotechnology & Bioprocessing

Dr. Noubar Afeyan, Flagship's Managing Partner and CEO, speaking on Investor Panel at BIO World Congress on Industrial Biotechnology & Bioprocessing

April 30, 2012

 Click here to see announcement.

Michigan Growth Capital Symposium Unveils Flagship Ventures' Noubar Afeyan as Keynote Speaker

Michigan Growth Capital Symposium Unveils Flagship Ventures' Noubar Afeyan as Keynote Speaker

April 24, 2012

Society for Biological Engineering Announces Inaugural Winners of Wang Award

Society for Biological Engineering Announces Inaugural Winners of Wang Award

April 17, 2012

NEW YORK – The Society for Biological Engineering (SBE) of the American Institute of Chemical Engineers (AIChE) has announced the inaugural winners of the D. I. C. Wang Award for Excellence in Biochemical Engineering. The inaugural recipients of the award, established in appreciation of Professor Daniel I.C. Wang of the Massachusetts Institute of Technology (MIT), are Noubar Afeyan of Flagship Ventures and James Swartz of Stanford University.

Shire Adds new Technology Platform and Phase 2 Product Candidate to its Regenerative Medicine Business

Shire Adds new Technology Platform and Phase 2 Product Candidate to its Regenerative Medicine Business

April 12, 2012
DUBLIN, April 12, 2012 /PRNewswire/ --